Business
Cencora Reports Fiscal 2026 First Quarter Results
CONSHOHOCKEN, Pa., February 04, 2026--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below
About this update from Cencora, Inc.
[{"type":"text","content":"Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year","length":78,"tagName":"p","attribs":{}},{"type":"text","content":"First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5%","length":69,"tagName":"p","attribs":{}},{"type":"text","content":"Adjusted Diluted EPS Guidance Range Reaffirmed at $17.45 to $17.75 for Fiscal 2026","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"Company Completes Acquisition of OneOncology","length":44,"tagName":"p","attribs":{}},{"type":"text","content":"CONSHOHOCKEN, Pa., February 04, 2026--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 9.4 percent to $4.08 in the fiscal first quarter from $3.73 in the prior year first quarter.","length":621,"tagName":"p"},{"type":"text","content":"Cencora is updating its outlook for fiscal year 2026. The Company does not provide forward-looking guidance on a GAAP basis as discussed below in Fiscal Year 2026 Expectations. Adjusted operating income guidance has been raised from the previous range of growth of 8% to 10% to growth of 11.5% to 13.5% primarily to reflect the completion of the acquisition of OneOncology and the performance of the U.S. Healthcare Solutions segment.","length":434,"tagName":"p"},{"type":"text","content":""Cencora began fiscal 2026 by delivering strong financial performance and advancing our strategy through the acquisition of OneOncology," said Robert P. Mauch, President and Chief Executive Officer of Cencora.","length":219,"tagName":"p"},{"type":"text","content":""Our ownership of OneOncology cements our specialty MSO footprint and deepens our partnership with physicians leading in cancer care," Mauch continued "As we continue to advance our leadership in specialty and execute our pharm...